Stocks
Olema Pharmaceuticals, Inc.OLMA
NASDAQHealthcareBiotechnology$7.11
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted therapies for breast cancer, with its lead candidate, palazestrant, in Phase 3 trials. Investors track the stock for its potential in the estrogen receptor-positive breast cancer market and its partnerships with larger pharmaceutical firms.
52W Range: $6.48-$36.26
Congressional Interest in Olema Pharmaceuticals, Inc. (OLMA)
No congressional trades have been disclosed for Olema Pharmaceuticals, Inc. (OLMA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading OLMA?
No congressional trades found for this stock.